| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Maternal Cell Contamination Study, STR Analysis
Test Code10262
CPT Codes
81265<br />
Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
3 mL
Other Acceptable Specimens
Whole blood collected in: ACD (yellow-top) tube or sodium heparin (green-top) tube
Instructions
This test is run in conjunction with either a fetal specimen (amniotic fluid, dissected chorionic villus (CVS) biopsy or products of conception) or a cord blood sample.
The assay cannot be run until fetal cultures are ready. The TAT is therfore dependent on the TAT of the fetal DNA test on the same patient.
Whole blood: Specimen stability is crucial. Store and ship room temperature immediately. Do not freeze.
The assay cannot be run until fetal cultures are ready. The TAT is therfore dependent on the TAT of the fetal DNA test on the same patient.
Whole blood: Specimen stability is crucial. Store and ship room temperature immediately. Do not freeze.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 8 days
Refrigerated: 8 days
Frozen: Unacceptable
Refrigerated: 8 days
Frozen: Unacceptable
Methodology
Multiplex Polymerase Chain Reaction • Fragment Analysis by Capillary Electrophoresis
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Run in conjunction with fetal clinical assay; Report available: 1 week
Clinical Significance
Maternal Cell Contamination Study, STR Analysis, provides assurance that test results from fetal specimens are not influenced by contaminating maternal material. This test also allows for establishing the proper maternal-fetal relationship between specimens by using sophisticated analysis of 15 highly polymorphic STR loci.
